nach oben

Erschienen in:

01.06.2010 | Nephrology - Original Paper

Association between N-terminal pro-brain natriuretic peptide and acute ischemic stroke in patients on chronic hemodialysis

verfasst von: Yong Kyun Kim, Seok Joon Shin, Sang-Hyun Ihm, Chan Seok Park, Hee-Yeol Kim, Young-Du Kim, Dong Suk Shim, Ho Cheol Song, Chul Woo Yang, Yong-Soo Kim, Euy Jin Choi

Erschienen in: International Urology and Nephrology | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

Plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) has been reported as a predictor for ischemic stroke in general population. However, predictive value of plasma NT-proBNP for acute ischemic stroke in patients on chronic hemodialysis has not been well established. The aim of this study was to determine whether NT-proBNP could predict acute ischemic stroke in patients on chronic hemodialysis.

Methods

This study was designed prospectively. Clinical, laboratory, and echocardiographic variables were assessed in 72 patients on chronic hemodialysis. The plasma levels of NT-proBNP were measured by immunoassay.

Results

During the follow-up period of 45 months, 11 patients had an acute ischemic stroke. The Kaplan–Meier plot showed an increased frequency of acute ischemic stroke in patients with plasma levels of NT-proBNP above the median values compared to patients with lower concentrations (P = 0.028). The multivariate Cox proportional hazard models showed that the NT-proBNP was a significant independent predictor of acute ischemic stroke after adjustment for age, sex, mean blood pressure, diabetes, serum cholesterol levels, left ventricular mass index, and left ventricular fractional shortening (HR 6.66, 95% CI, 1.22–36.48, P = 0.029).

Conclusions

Our data suggest that plasma NT-proBNP levels predict the risk of acute ischemic stroke in patients on chronic hemodialysis.

Hall C (2004) Essential biochemistry and physiology of (NT-pro)BNP. Eur J Heart Fail 6:257–260CrossRefPubMed

Bruneau BG, Piazza LA, de Bold AJ (1997) BNP gene expression is specifically modulated by stretch and ET-1 in a new model of isolated rat atria. Am J Physiol 273:H2678–H2686PubMed

McDonagh TA, Cunningham AD, Morrison CE, McMurray JJ, Ford I, Morton JJ et al (2001) Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population. Heart 86:21–26CrossRefPubMed

Wallen T, Landahl S, Hender T, Nakao K, Saito Y (1997) Brain natriuretic peptide predicts mortality in the elderly. Heart 77:264–267CrossRefPubMed

Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P (2005) N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 293:1609–1616CrossRefPubMed

Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T et al (2004) Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 350:655–663CrossRefPubMed

Takahashi T, Nakamura M, Onoda T, Ohsawa M, Tanno K, Itai K et al. (2009) Predictive value of plasma B-type natriuretic peptide for ischemic stroke: a community-based longitudinal study. Atherosclerosis. doi:10.1016/j.atherosclerosis.2009.04.029

Satyan S, Light RP, Agarwal R (2007) Relationships of N-terminal pro-B-natriuretic peptide and cardiac troponin T to left ventricular mass and function and mortality in asymptomatic hemodialysis patients. Am J Kidney Dis 50:1009–1019CrossRefPubMed

Sharma R, Gaze DC, Pellerin D, Mehta RL, Gregson H, Streather CP et al (2006) Raised plasma N-terminal pro-B-type natriuretic peptide concentrations predict mortality and cardiac disease in end-stage renal disease. Heart 92:1518–1519CrossRefPubMed

10.

Sommerer C, Beimler J, Schwenger V, Heckele N, Katus HA, Giannitsis E et al (2007) Cardiac biomarkers and survival in haemodialysis patients. Eur J Clin Invest 37:350–356CrossRefPubMed

11.

Apple FS, Murakami MM, Pearce LA, Herzog CA (2004) Multi-biomarker risk stratification of N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for all-cause death. Clin Chem 50:2279–2285CrossRefPubMed

12.

Zoccali C, Mallamaci F, Benedetto FA, Tripepi G, Parlongo S, Cataliotti A et al (2001) Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol 12:1508–1515PubMed

13.

Madsen LH, Ladefoged S, Corell P, Schou M, Hildebrandt PR, Atar D (2007) N-terminal pro brain natriuretic peptide predicts mortality in patients with end-stage renal disease in hemodialysis. Kidney Int 71:548–554CrossRefPubMed

14.

Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R et al (1995) Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European cooperative acute stroke study (ECASS). JAMA 274:1017–1025CrossRefPubMed

15.

Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H et al (1989) Recommendations for quantitation of the left ventricle by two-dimensional echocardiography: American society of echocardiography committee on standards, subcommittee on quantitation of two-dimensional echocardiograms. J Am Soc Echocardiogr 2:358–367PubMed

16.

de Simone G, Devereux RB, Roman MJ, Alderman MH, Laragh JH (1994) Relation of obesity and gender to left ventricular hypertrophy in normotensive and hypertensive adults. Hypertension 23:600–606PubMed

17.

de Simone G, Devereux RB, Roman MJ, Ganau A, Saba PS, Alderman MH et al (1994) Assessment of left ventricular function by the midwall fractional shortening/end-systolic stress relation in human hypertension. J Am Coll Cardiol 23:1444–1451CrossRefPubMed

18.

O’Brien E, Asmar R, Beilin L, Imai Y, Mancia G, Mengden T et al (2005) Practice guidelines of the European society of hypertension for clinic, ambulatory and self blood pressure measurement. J Hypertens 23:697–701CrossRefPubMed

19.

Delmez JA, Yan G, Bailey J, Beck GJ, Beddhu S, Cheung AK et al (2006) Hemodialysis (HEMO) Study Group. Cerebrovascular disease in maintenance hemodialysis patients: results of the HEMO Study. Am J Kidney Dis 47:131–138CrossRefPubMed

20.

Seliger SL, Gillen DL, Tirschwell D, Wasse H, Kestenbaum BR, Stehman-Breen CO (2003) Risk factors for incident stroke among patients with end-stage renal disease. J Am Soc Nephrol 14:2623–2631CrossRefPubMed

21.

Longenecker JC, Coresh J, Powe NR, Levey AS, Fink NE, Martin A et al (2002) Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE study. J Am Soc Nephrol 13:1918–1927CrossRefPubMed

22.

Krane V, Krieter DH, Olschewski M, März W, Mann JF, Ritz E et al (2007) Wanner C. Dialyzer membrane characteristics and outcome of patients with type 2 diabetes on maintenance hemodialysis. Am J Kidney Dis 49:267–275CrossRefPubMed

23.

Rost NS, Wolf PA, Kase CS, Kelly-Hayes M, Silbershatz H, Massaro JM et al (2001) Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke 32:2575–2579CrossRefPubMed

24.

Chou CY, Kuo HL, Lin HH, Liu JS, Liu YL, Huang CC (2009) C-reactive protein predicts ischaemic stroke in haemodialysis patients. Int J Clin Pract 63:243–248CrossRefPubMed

25.

Yukiiri K, Hosomi N, Naya T, Takahashi T, Ohkita H, Mukai M et al (2008) Plasma brain natriuretic peptide as a surrogate marker for cardioembolic stroke. BMC Neurol 8:45CrossRefPubMed

26.

National Institutes of Health, USRDS (2005) 2005 annual data report, Bethesda, MD, p 182

27.

Toyoda K, Fujii K, Fujimi S, Kumai Y, Tsuchimochi H, Ibayashi S et al (2005) Stroke in patients on maintenance hemodialysis: a 22-year single-center study. Am J Kidney Dis 45:1058–1066CrossRefPubMed

Titel: Association between N-terminal pro-brain natriuretic peptide and acute ischemic stroke in patients on chronic hemodialysis
verfasst von: Yong Kyun Kim
Seok Joon Shin
Sang-Hyun Ihm
Chan Seok Park
Hee-Yeol Kim
Young-Du Kim
Dong Suk Shim
Ho Cheol Song
Chul Woo Yang
Yong-Soo Kim
Euy Jin Choi
Publikationsdatum: 01.06.2010
Verlag: Springer Netherlands
Erschienen in: International Urology and Nephrology / Ausgabe 2/2010
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-009-9689-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Bei Herzinsuffizienz muss „Eisenmangel“ neu definiert werden!

16.05.2024 Herzinsuffizienz Nachrichten

Bei chronischer Herzinsuffizienz macht es einem internationalen Expertenteam zufolge wenig Sinn, die Diagnose „Eisenmangel“ am Serumferritin festzumachen. Das Team schlägt vor, sich lieber an die Transferrinsättigung zu halten.

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2010

Clinical and metabolic risk factor evaluation in young adults with kidney stones

Association of macroalbuminuria with oxidized LDL and TGF-β in type 2 diabetic patients: a case–control study

The clearance of unidentified uremic solutes (with molecular weight under 5 kDa) plays an important role in hemodialyzer selection

Ten years single surgeon experience with botulinum toxin in the urinary tract; clinical observations and research discovery

Renal replacement therapy for stage 5 chronic kidney disease in the Cayman Islands

An unusual complication of sickle cell trait: intraureter thrombus